Analysis of the MammaPrint breast cancer assay in an older US General Hospital population.

Publication Name: Poster, AACR 2007

Author(s): Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, Tako J. Bruinsma, Annuska M. Glas,

Breast cancer patients with similar pathological staging can have markedly different rates of disease-free and overall survival. A key challenge in breast cancer management is to accurately determine a patient’s risk of developing distant metastasis at the time of primary diagnosis. This information can then be used to tailor metastasis-preventing treatment for high-risk patients. A 70-gene microarray gene expression signature was previously discovered at the Netherlands Cancer Institute (NKI) to identify younger breast cancer patients (age < 55 years) with lymph-node negative disease who are at low risk of developing distant metastasis and might therefore be spared further adjuvant chemotherapy.(1, 2) This diagnostic test known as “MammaPrint” was recently validated in an independent cohort.(3) Many breast cancer patients, however, are older and post-menopausal with a lower overall risk of distant metastasis. A molecular diagnostic test with high negative predictive value for distant metastasis in this subgroup could spare many older women adjuvant treatment.

See Poster